As in vitro motility and invasiveness was strongly activated by HGF, a circulating growth factor that is considered a poor prognostic marker in ovarian cancer patients [22], control and silenced cells were further engineered to secrete HGF in order to enhance their metastatic potential. This evidence concerns the gene HGF and ovarian carcinoma.